Sign In
Section Navigation
Common TitleDRIVE SHIFT
Official Title A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to doravirine plus lamivudine plus tenofovir disoproxil fumarate in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
Phase Phase III
ClinicalTrials.gov NCT02397096
Treatments
Doravirine
Doravirine Pifeltro

Doravirine

Tradename:PifeltroOther Names:DORClass:Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)
,
Doravirine-Tenofovir DF-Lamivudine
Doravirine-Tenofovir DF-Lamivudine Delstrigo

Doravirine-Tenofovir DF-Lamivudine

Tradename:DelstrigoOther Names:DOR-TDF-3TC, Doravirine-Tenofovir disoproxil fumarate-LamivudineClass:Single-Tablet Regimens
Categories Treatment-ExperiencedSwitch/Simplification
Funding
IndustryMerck Sharp & Dohme Corp
References
  • Johnson M, Kumar P, Molina JM, et al. Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial. J Acquir Immune Defic Syndr. 2019;81:463-72.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.